Tarasiuk K, Pejsak Z, Hogg A, Carlson M P
Veterinary Research Institute, Pulawy, Poland.
Can Vet J. 1994 Apr;35(4):233-8.
A trial was performed in a swine research facility to ascertain the protection provided by a polyvalent Actinobacillus pleuropneumoniae (APP) bacterin containing serotypes 1, 3, 5 and 9. The test animals consisted of 60, eight-week-old, piglets, which were randomly divided into four main groups. The four main groups were further divided into three sub-groups (I, II, III) of five pigs each. Subgroup I was vaccinated intramuscularly, sub-group II was vaccinated subcutaneously, and sub-group III served as the unvaccinated control group. Each main group was challenged with a single APP serotype (1, 3, 5 or 9). Criteria for evaluation of the bacterin efficacy were mortality, lung lesions, pleural adhesions, and isolation of APP from tonsil or lung. Significant effects of vaccination over nonvaccination were reduced mortality, lung lesions, pleural adhesions, and isolations of APP from tonsil and lung. There were no significant differences between the intramuscular and subcutaneous routes of vaccination. It was concluded that the four-way APP bacterin used in this study provided satisfactory protection against homologous challenge. Evidence of protection was lower mortality and lung lesions and increased daily weight gains in vaccinates as compared with controls.
在一个猪研究设施中进行了一项试验，以确定一种包含1、3、5和9型血清型的多价胸膜肺炎放线杆菌（APP）菌苗所提供的保护作用。试验动物包括60头8周龄的仔猪，它们被随机分为四个主要组。这四个主要组又进一步分为三个亚组（I、II、III），每组五头猪。亚组I通过肌肉注射进行接种，亚组II通过皮下注射进行接种，亚组III作为未接种的对照组。每个主要组用单一的APP血清型（1、3、5或9）进行攻毒。评估菌苗效力的标准包括死亡率、肺部病变、胸膜粘连以及从扁桃体或肺部分离出APP。接种疫苗相对于未接种疫苗的显著效果是降低了死亡率、肺部病变、胸膜粘连以及从扁桃体和肺部分离出APP的情况。肌肉注射和皮下注射接种途径之间没有显著差异。得出的结论是，本研究中使用的四价APP菌苗对同源攻毒提供了令人满意的保护。与对照组相比，接种疫苗组保护的证据是死亡率和肺部病变降低，以及日增重增加。
